Idarubicin overcomes P-glycoprotein-related multidrug resistance: Comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines

Leukemia Research

Volumn 23, Issue 6, 1999, Pages 539-548

  Roovers, Dick J ^a   Van Vliet, Marja ^a   Bloem, Andries C ^a   Lokhorst, Henk M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Apoptosis; Idarubicin; Multidrug resistance; Multiple myeloma; P glycoprotein

Indexed keywords

ANTHRACYCLINE; CERUBINE; DAUNORUBICIN; DOXORUBICIN; DOXORUBICINOL; GLYCOPROTEIN P; IDARUBICIN; IDARUBICINOL; LIPOCORTIN 5; UNCLASSIFIED DRUG; VERAPAMIL;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; IDARUBICIN; MULTIPLE MYELOMA; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0033000043     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00041-7     Document Type: Article

References (32)

1. Alberti D.S., Salmon S.E. Adriamycin in the treatment of alkylator-resistant multiple myeloma. A pilot study. Cancer Chemother. Rep. 59:1975;345-350.
2. Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med. 310:1984;1353-1356.
3. Dalton W.S., Grogan T.M., Rybski J.A. et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood. 73:1989;747-752.
4. Epstein J., Barlogie B. Tumor resistance to chemotherapy associated with expression of the multidrug resistance phenotype. Cancer Bull. 41:1989;41-44.
5. Sonneveld P., Durie B.G.M., Lokhorst H.M. et al. Modulation of multidrug resistance by cyclosporin. Lancet. 340:1992;255-259.
6. Raaijmakers HGP, Izquierdo MAI, Lokhorst HM et al. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998;91:1029-36.
7. Scheffer G.L., Wijngaard P.L.J., Flens M.J. et al. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1:1995;1-3.
8. Cole S.P.C., Bhardwaj G., Gerlach J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
9. Pettersson M., Jernberg-Wiklund H., Larsson L.G. et al. Expression of the Bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood. 79:1992;495-502.
10. Tu Y., Xu F., Liu J. et al. Upregulated expression of Bcl-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood. 88:1996;1805-1812.
11. Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 79:1992;3267-3273.
12. List A.F., Grimm M., Glinamann-Gibson B. et al. Relative cytotoxicity and P-glycoprotein avidity of idarubicin, daunorubicin and mitoxantrone in multidrug resistant (MDR) cell lines. Proc. Am. Assoc. Cancer Res. 35:1993;421.
13. Ross D, Tong Y, Comblatt B. Idarubicin (IDA) is less vulnerable to transport- mediated Multidrug Resistance (MDR) than its metabolite Idarubicinol (IDA-ol) or Daunorubicin. Blood. 10(1):1993;1015. Abstract.
14. Carella A.M., Berman E., Maraone M.P. et al. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologia. 75:1990;154-169.
15. Matsuoka Y., Moore G.E., Yagi Y., Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Bio. Med. 125:1967;1246-1250.
16. Flens M.J., Izquierdo M.A., Scheffer G.L. et al. Immunochemical dtection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 54:1994;4557-4563.
17. Krishan A, Ganapathi V Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res. 40:1980;3900-3985.
18. Herweijer H., van den Engh G., Nooter K. A rapid and sensitive flow cytometric method for the detection of multidrug-resistant cells. Cytometry. 10:1989;463-468.
19. Ross D.D., Doyle L.A., Yang W. et al. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem. Pharmacol. 50:1995;1673-1683.
20. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precize and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119:1989;203-210.
21. Koopman G., Reutelingsperger C.P.M., Kuijten G.A.M. et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1994;1415-1420.
22. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods. 184:1995;39-51.
23. Belloc F., Lacombe F., Dumain P. et al. Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry. Cytometry. 13:1992;880-885.
24. Capranico G., Zunino F., Kohn K.W. et al. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry. 29:1990;562-569.
25. Tarasiuk J., Frézard F., Garnier-Suillerot A. et al. Anthracycline incorporation in human lymphocytes: kinetics of uptake and nuclear concentration. Biochim. Biophys. Acta. 1013:1989;109-117.
26. Frezard F., Garnier-Suillerot A. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur. J. Biochem. 196:1991;483-491.
27. Spoelstra E.C., Westerhoff H.V., Dekker H. et al. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur. J. Biochem. 207:1992;567-579.
28. Mankhetkorn S., Dubru F., Hesschenbrouck J. et al. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol. Pharm. 49:1996;532-539.
29. Facchetti I., Grandi P., Cicchi P. et al. Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. Anti-Cancer Drug Des. 6:1991;385-397.
30. Berman E., McBride M., Clarkson B. Clinical implications of idarubicin pharmacology. Haematol. Blood Transfus. 34:1992;295.
31. Friche E., Buhl Jensen P., Roed H. et al. In vitro circumvention of anthracycline-resistance in Ehrlich ascites tumour by anthracycline analogues. Biochem. Pharm. 39:1990;1721.
32. Lampidis T.J., Kolonias D., Podona T. et al. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry. 36:1997;2679-2685.